Non-Hodgkin lymphoma relapse is not a cause for increased anxiety if recurrence is quickly addressed with well tolerated therapy.
ASCO's CancerLinQ go live later this year, ushering in what they described as a transformative era of big data-driven precision cancer care.
ESMO guidelines account for new criteria in renal cell carcinoma, providing guidance on recommended therapies as new data and kinase inhibitors have emerged.
[Blood and Lymphatic Cancer: Targets and Therapy] Myeloma displays considerable heterogeneity and, over time, control of disease can be lost. New strategies to combat myeloma incorporate risk stratification to provide more individualized therapy.
Fall Digital Issue
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Multiple myeloma: Optimal management and long-term disease control
- Coffee May Decrease Risk of Malignant Melanoma
- ASCO Announces Chronic Leukemia Treatment as Cancer Advance of the Year
- LDVP Regimen Following Radiotherapy Effective for Stage III/IV T-Cell Lymphoma
- Bevacizumab Plus Temozolomide Produces Low Response in Newly-Diagnosed Glioblastoma
- European Society for Medical Oncology (ESMO) Renal Cell Carcinoma Practice Guidelines
- Smoking Increases Risk of Side Effects, Recurrence in Prostate Cancer
- Panitumumab Plus Radiotherapy Ineffective in Head and Neck Cancer
- No Non-Inferiority in Standard Regimen vs. Capecitabine for Breast Cancer
- Surveillance Until Rituximab Retreatment Does Not Increase Anxiety in Non-Hodgkin Lymphoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|